Tumor News and Research

RSS

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

21 Feb 2014

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

Pediatric Cancer Genome Project identifies genetic alteration in brain tumor ependymoma

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The research appears February 19 as an advanced online publication in the scientific journal Nature.

20 Feb 2014

Certain fragments of DNA shed by tumors can be used to non-invasively screen for early-stage cancers

Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.

20 Feb 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Oncologists and cancer patients could improve the results of drug therapies by making real-time decisions about treatment options using an innovation developed in Purdue University's College of Pharmacy.

20 Feb 2014

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.

20 Feb 2014

New method enables scientists to print tissue constructs with blood vessels

A new bioprinting method developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard School of Engineering and Applied Sciences (SEAS) creates intricately patterned 3D tissue constructs with multiple types of cells and tiny blood vessels.

20 Feb 2014

Cook Medical launches new treatment option for otolaryngologists

Cook Medical has launched a new treatment option for otolaryngologists (ear, nose and throat specialists) who repair the dura mater following cerebrospinal fluid (CSF) leaks at the base of the skull. Cook's Biodesign Duraplasty Graft is the latest Biodesign product from Cook Medical's Otolaryngology—Head and Neck Surgery clinical division.

From COOK MEDICAL INC. 20 Feb 2014

Ways to help manage chronic pain

Musculoskeletal pain of the bone, joint and muscles is one of the most common reasons for primary care visits in the United States. According to a literature review appearing in a recent issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), chronic pain, or pain that persists beyond an expected period of healing, is estimated to affect 100 million Americans.

20 Feb 2014

New biologic drug to prevent growth of ovarian cancer cells

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.

20 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

The National Institutes of Health has awarded grants totaling $3 million for two nanoparticle research projects in which Penn State bioengineer Jian Yang is co-principal investigator.

19 Feb 2014

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

19 Feb 2014

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards are the centerpiece of the MRA research fund, which seeks to promote transformational melanoma research for swift clinical implementation.

18 Feb 2014

Scientists develop mathematical method for classifying forms of glioblastoma

Scientists at The Wistar Institute have developed a mathematical method for classifying forms of glioblastoma, an aggressive and deadly type of brain cancer, through variations in the way these tumor cells "read" genes. Their system was capable of predicting the subclasses of glioblastoma tumors with 92 percent accuracy. With further testing, this system could enable physicians to accurately predict which forms of therapy would benefit their patients the most.

18 Feb 2014

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced the launch of Hereditary Colorectal Cancer DNA Insight, the company's premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient's risk of developing certain types of cancer.

18 Feb 2014

Tumor News and Research

Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Pediatric Cancer Genome Project identifies genetic alteration in brain tumor ependymoma

Certain fragments of DNA shed by tumors can be used to non-invasively screen for early-stage cancers

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

New method enables scientists to print tissue constructs with blood vessels

Cook Medical launches new treatment option for otolaryngologists

Ways to help manage chronic pain

New biologic drug to prevent growth of ovarian cancer cells

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

Matching the right tumor with the right drug

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Scientists develop mathematical method for classifying forms of glioblastoma

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News